Actuate Therapeutics’ (ACTU) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.02) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.99) EPS and FY2029 earnings at $0.21 EPS.

Separately, Craig Hallum initiated coverage on shares of Actuate Therapeutics in a research report on Tuesday, April 22nd. They issued a “buy” rating and a $21.00 price target for the company. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $20.50.

Actuate Therapeutics Price Performance

Shares of ACTU stock opened at $7.68 on Monday. Actuate Therapeutics has a 52 week low of $5.47 and a 52 week high of $11.99. The firm has a 50 day moving average of $7.08 and a two-hundred day moving average of $7.96.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Insider Buying and Selling

In related news, Director Equity Cof Lp Bios purchased 71,428 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The shares were purchased at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the purchase, the director directly owned 196,428 shares of the company’s stock, valued at $1,374,996. The trade was a 57.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Aaron G.L. Fletcher purchased 71,428 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The shares were bought at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the purchase, the director directly owned 196,428 shares in the company, valued at $1,374,996. This represents a 57.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 214,284 shares of company stock worth $1,499,988 in the last ninety days. 69.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACTU. Chicago Partners Investment Group LLC purchased a new position in Actuate Therapeutics during the 1st quarter worth $70,000. Sfmg LLC purchased a new position in Actuate Therapeutics during the 1st quarter worth $74,000. Envestnet Asset Management Inc. purchased a new position in Actuate Therapeutics during the 4th quarter worth $83,000. OMERS ADMINISTRATION Corp purchased a new position in Actuate Therapeutics during the 4th quarter worth $84,000. Finally, Bank of America Corp DE grew its position in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after purchasing an additional 15,267 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.